Gilead Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Gilead Sciences CEO'su Dan O'Day, Mar2019 tarihinde atandı, in görev süresi 5.67 yıldır. in toplam yıllık tazminatı $ 22.61M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.7% maaş ve 92.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.04% ine doğrudan sahiptir ve bu hisseler R$ 268.91M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 6.5 yıldır.

Anahtar bilgiler

Dan O'Day

İcra Kurulu Başkanı

US$22.6m

Toplam tazminat

CEO maaş yüzdesi	7.7%
CEO görev süresi	5.7yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	6.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dan O'Day'un ücretlendirmesi Gilead Sciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$126m
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$485m
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 22.61M ), BR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.72M ).

Tazminat ve Kazançlar: Dan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dan O'Day (60 yo)

5.7yrs

Görev süresi

US$22,607,690

Tazminat

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel P. O'Day	Chairman & CEO	5.7yrs	US$22.61m	0.040% R$ 268.9m
Andrew Dickinson	Chief Financial Officer	5yrs	US$8.11m	0.011% R$ 75.3m
Deborah Telman	Executive VP of Corporate Affairs	2.3yrs	US$5.27m	0.0017% R$ 11.4m
Johanna Mercier	Chief Commercial Officer	5.3yrs	US$8.59m	0.0059% R$ 39.7m
Merdad Parsey	Chief Medical Officer	5yrs	US$8.39m	0.0080% R$ 54.0m
Sandra Patterson	Senior VP	1.7yrs	Veri yok	0.0029% R$ 19.9m
Jacquie Ross	Vice President of Investor Relations	3.8yrs	Veri yok	Veri yok
Jyoti Mehra	Executive Vice President of Human Resources	5.3yrs	Veri yok	Veri yok
Linda Higgins	Senior Vice President of Research	4.8yrs	Veri yok	Veri yok
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	Veri yok	Veri yok
Flavius Martin	Executive Vice President of Research	3.6yrs	Veri yok	Veri yok
William Grossman	Senior Vice President & Therapeutic Area Head of Gilead Oncology	3.3yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: GILD34 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel P. O'Day	Chairman & CEO	5.7yrs	US$22.61m	0.040% R$ 268.9m
Anthony Welters	Lead Independent Director	4.1yrs	US$444.92k	0.00082% R$ 5.5m
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	Veri yok
Jacqueline Barton	Independent Director	6.8yrs	US$429.92k	0.0020% R$ 13.3m
Eugene Schiff	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Schooley	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Harish Manwani	Independent Director	6.5yrs	US$414.92k	0.0010% R$ 7.0m
John Mellors	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Francis Chisari	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Paul Klotman	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Kelly Kramer	Independent Director	8.3yrs	US$434.92k	0.00011% R$ 743.2k
Joel Huff	Chairperson of Scientific Advisory Board	no data	Veri yok	Veri yok

6.5yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GILD34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.5 yıldır).

Gilead Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Recent updates

Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş